Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the Sugar Business, net sales were below the level of the same period last year due mainly to lower selling prices following the price revision in November last year, while profit exceeded the level of the same period last year as a result of lower costs for procuring raw sugar, manufacturing and other activities. In the Bio Business, profit declined due to higher production costs resulting from rising prices.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥8,637 million (YoY -1.7%) |
| Operating profit | ¥831 million (YoY +18.8%) |
| Ordinary income | ¥1,094 million (YoY +13.6%) |
| Profit attributable to owners of the parent | ¥800 million (YoY +11.1%) |
| Net income per share | ¥29.09 |
| Equity ratio | End of the current fiscal period 65.5 / End of previous period 64.8 |
| Total assets | ¥33,585 million |
| Net assets | ¥22,002 million |
| Full-year earnings forecast | Net Sales ¥32,100 million (YoY -2.7%) / Operating profit ¥2,400 million (YoY -21.3%) / Ordinary income ¥2,600 million (YoY -22.1%) / Net income ¥1,800 million (YoY -34.9%) |
| Revision to Earnings Forecast | Not disclosed → No revision（No） |
| Annual Dividend Forecast | ¥20 → ¥16（-20.0%） |
| Segment revenue | Sugar business ¥8,222 million (YoY -1.7%), Bio Business ¥443 million (YoY -2.1%), Other ¥35 million (YoY +4.7%) |
| Segment profit | Sugar business ¥1,076 million (YoY +12.6%), Bio Business ¥92 million (YoY -9.7%), Other ¥21 million (YoY +18.4%) |
| Depreciation and amortization | ¥150 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No material changes (number and names of companies not stated) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No (no target participants specified) |
| Issued Shares at Period-End | 35,000,000 |
| Treasury Shares at Period-End | 7,480,346 |
| Factors Behind Changes in Business Performance | In the Sugar Business, net sales were below the level of the same period last year due mainly to lower selling prices following the price revision in November last year, while profit exceeded the level of the same period last year as a result of lower costs for procuring raw sugar, manufacturing and other activities. In the Bio Business, profit declined due to higher production costs resulting from rising prices. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Sugar Business, net sales declined due mainly to lower selling prices following the price revision in November last year, while profit increased as a result of lower costs for procuring raw sugar, manufacturing and other activities. In the Bio Business, profit declined due to higher production costs resulting from rising prices.